[Back to Issue 6 ToC] [Back to Journal Contents] [Back to Biochemistry (Moscow) Home page]

Nanoantibodies for Detection and Blocking of Bioactivity of Human Vascular Endothelial Growth Factor A165

S. V. Tillib, T. I. Ivanova, E. Yu. Lyssuk*, S. S. Larin, A. V. Kibardin, E. V. Korobko, P. N. Vikhreva, N. V. Gnuchev, G. P. Georgiev, and I. V. Korobko

Institute of Gene Biology, Russian Academy of Sciences, ul. Vavilova 34/5, 119334 Moscow, Russia; fax: (499) 135-4105; E-mail: elenlys@gmail.com

* To whom correspondence should be addressed.

Received February 17, 2012; Revision received March 12, 2012
Nanoantibodies (single-domain antibodies, nanobodies) derived from noncanonical single-chain immunoglobulins provide an attractive tool for in vitro and in vivo diagnostics as well as for development of targeted drugs for clinical use. Nanoantibodies against several clinically important targets have been developed and are actively investigated. However, no development of nanoantibodies against vascular endothelial growth factor VEGF-A165 has been reported. We describe here the generation of nanoantibodies derived from single-chain Bactrian camel immunoglobulins directed against VEGF-A165. We demonstrate that these nanoantibodies are suitable for enzyme-linked immunoassay to quantify human VEGF-A165 as well as for blocking its activity. Our results provide a basis for diagnostic kit development for quantification of VEGF-A165, which emerges as a biomarker useful in various pathological conditions. In addition, the nanoantibodies might be used for development of therapeutic molecules targeting VEGF-A165-dependent pathological neoangiogenesis.
KEY WORDS: nanoantibodies, human vascular endothelial growth factor VEGF-A165, diagnostics, ELISA, VEGF-A165 inhibitor

DOI: 10.1134/S0006297912060132